KCA
Search
- Page Path
- HOME > Search
Case Reports
- Pleural Metastasis as Initial Presentation of Occult Gastric Cardia Cancer: A Possible Role of PET-CT in Diagnosis
- So Young Yoon, Jeong Hwan Kim, Wan Seop Kim, Hyun Woo Chung, Mark Hong Lee, Sung Yong Kim, Yo Han Cho
- Cancer Res Treat. 2014;46(4):415-418. Published online July 18, 2014
- DOI: https://doi.org/10.4143/crt.2013.068
-
Abstract
PDF
PubReader
ePub - We report on a case of malignant pleural effusion as initial metastatic presentation of occult gastric cardia cancer in a young woman. To the best of our knowledge, this is the first report of gastric adenocarcinoma metastasized to pleura as an initial presentation. Location of cardia and signet ring cell histology may contribute to the manifestation. Utilization of PET/CT was helpful for proper diagnosis. For patients with such distinct clinical presentations, it would be appropriate to consider gastric cancer as one of the possible primary sites.
- 11,337 View
- 59 Download
- Hepatic Metastases of Gastric Adenocarcinoma Showing Metabolic Remission on FDG-PET Despite an Increase in Size on CT
- So Young Yoon, Sung-Yong Kim, Yo-Han Cho, Hyun Woo Chung, Young So, Hong M Lee
- Cancer Res Treat. 2009;41(2):100-103. Published online June 30, 2009
- DOI: https://doi.org/10.4143/crt.2009.41.2.100
-
Abstract
PDFPubReaderePub
We report a gastric adenocarcinoma patient with liver metastases. The metastases showed progression on computed tomography (CT), but this was not true progression in terms of metabolic activity according to 18F-fluorodeoxyglucose positron emission tomography (FDG-PET). Discordance between size criteria and metabolic criteria has been reported in liver gastrointestinal stromal tumors, hepatomas, and renal cell carcinomas after dramatic responses with targeted therapies such as imatinib, sorafenib, and sunitinib (
1 -6 ). However, this discordance has been rarely reported in liver metastases of gastric adenocarcinoma when treated with conventional chemotherapy.-
Citations
Citations to this article as recorded by
- Phase II trial evaluating the efficacy of sorafenib (BAY 43‐9006) and correlating early fluorodeoxyglucose positron emission tomography–CT response to outcome in patients with recurrent and/or metastatic head and neck cancer
Yassine Lalami, Camillo Garcia, Patrick Flamen, Lieveke Ameye, Marianne Paesmans, Ahmad Awada
Head & Neck.2016; 38(3): 347. CrossRef - A Case of Long-Term Complete Remission of Advanced Gastric Adenocarcinoma with Liver Metastasis
Ch'angbum Rim, Jung-Ae Lee, Soojung Gong, Dong Wook Kang, Heebum Yang, Hyun Young Han, Nae Yu Kim
Journal of Gastric Cancer.2016; 16(2): 115. CrossRef - PRELIMINARY EVALUATION OF SERIAL 18FDG‐PET/CT TO ASSESS RESPONSE TO TOCERANIB PHOSPHATE THERAPY IN CANINE CANCER
Amy K. LeBlanc, Ashley N. Miller, Gina D. Galyon, Tamberlyn D. Moyers, Misty J. Long, Alan C. Stuckey, Jonathan S. Wall, Federica Morandi
Veterinary Radiology & Ultrasound.2012; 53(3): 348. CrossRef - Phase II study of sunitinib as second-line treatment for advanced gastric cancer
Yung-Jue Bang, Yoon-Koo Kang, Won K. Kang, Narikazu Boku, Hyun C. Chung, Jen-Shi Chen, Toshihiko Doi, Yan Sun, Lin Shen, Shukui Qin, Wai-Tong Ng, Jennifer M. Tursi, Maria J. Lechuga, Dongrui Ray Lu, Ana Ruiz-Garcia, Alberto Sobrero
Investigational New Drugs.2011; 29(6): 1449. CrossRef
- Phase II trial evaluating the efficacy of sorafenib (BAY 43‐9006) and correlating early fluorodeoxyglucose positron emission tomography–CT response to outcome in patients with recurrent and/or metastatic head and neck cancer
- 8,493 View
- 57 Download
- 4 Crossref
First
Prev
